Although the clinical development of Biogen’s antisense product Spinraza (nusinersen) for spinal muscular atrophy (SMA) in around five years is a remarkable achievement, it does mean the long-term effects of the product are relatively unknown.
In recommending approval of the drug on April 21 following review by the Committee on Medicinal Products for Human Use...